AMW GmbH Further Strengthens Leadership Team by Appointing Dr. Joerg Serafimov to Managing Director and Promoting Senior Corporate Executives to C-Level Positions
Warngau, Germany, March 24, 2026
AMW GmbH, a specialty pharmaceutical company focused on biodegradable controlled-release drug delivery systems, today announced a substantial strengthening of its management team to further execute its growth strategy. Dr. Joerg Serafimov, the Company’s Chief Business Officer since January 2024, will join Philipp Karbach, CEO of AMW GmbH, as managing director. Furthermore, Matthias Dittmer, Vice President Finance and IT since October 2023, and Kerstin Ledermann, Vice President People and General Administration since July 2024, have both been appointed to C-level positions as Chief Financial Officer and Chief People Officer, respectively.
“I am honored to take on the position of managing director in addition to my established role as Chief Business Officer,” said Dr. Joerg Serafimov, CBO of AMW GmbH. “We have made significant progress within the last months and years, which testifies to the excellent team spirit and the high level of cooperation and trust within our management team and beyond. Backed by a trustful relationship with our longstanding and new investors, I highly welcome the opportunity to assume even more responsibility in shaping AMW’s future together with Philipp and this highly experienced team. And I would like to express my warmest congratulations to Matthias and Kerstin on their new positions within our leadership group.”
“I am delighted that our new investors Ren Life Sciences and Juno Capital, who recently joined as shareholders in AMW, fully support our chosen path and have followed my suggestions to expand our management team by appointing Joerg as managing director of the Company,” said Philipp Karbach, CEO and shareholder of AMW GmbH. “This marks another step in executing on our chosen growth path. Joerg and I have been working together in a spirit of mutual trust for over two years now and I am very much looking forward to building even more on his expertise in his new role in the future. Additionally, we are very happy to welcome Matthias and Kerstin to our C-level group. This reflects their outstanding work over the past few years and will be the backbone of our strategic growth course.”
Dr. Joerg Serafimov is an experienced business leader with a track record of profitable growth in originator specialty drugs, generics and B2B business. With more than 15 years of professional experience in the pharmaceutical industry and management consulting, he combines a strong strategic business planning mindset with a profound commercial operations background. Dr. Serafimov has served as Chief Business Officer of AMW GmbH since January 2024.
Matthias Dittmer is a finance executive with 15 years of leadership experience in controlling and financial group reporting as well as implementing ERP systems in complex, highly regulated industries with international structures. Mr. Dittmer assumed responsibility for the finance and IT departments at AMW GmbH in October 2023.
Kerstin Ledermann is an experienced manager and generalist with strategic and operational expertise. She has a track record of more than 20 years as Head of Human Resources and member of the management of internationally active medium-sized companies in trade and industry. Mrs. Ledermann has been heading the People and General Administration department at AMW GmbH since July 2024.
More information on AMW’s management can be found on our website: https://amw-pharmaceuticals.com/en/about-us/#management
###
About AMW GmbH:
AMW GmbH is a specialty pharmaceutical company focused on biodegradable implants, providing patients and partners access to value-added medicines for improved adherence and cost-effective therapies. The Company covers the entire value chain, from (co-)development to manufacturing and international commercialization.
AMW GmbH has two approved pharmaceutical products: implants releasing goserelin or leuprorelin respectively, which are distributed worldwide via direct sales and out-licensing. In Germany, leuprorelin is marketed as Leugon® by AMW’s fully owned subsidiary Endomedica GmbH. Based on its unparalleled expertise in formulation development, the Company collaborates with pharma and biotech partners worldwide to develop and manufacture high-quality products and life-cycle solutions.
AMW GmbH is based in Warngau near Munich, Germany.
For further information, please contact: